Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

University of Alabama at Birmingham · with National Institute of Neurological Disorders and Stroke (NINDS) · NCT03759522

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
120
US sites recruiting
1
Study start
February 3, 2019
Record last updated
June 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical [F-18]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer [F-18]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with [F-18]DPA-714-PET/MRI.

Being studied: DPA-714 PET/MRI

Conditions: Fibromyalgia; Chronic Fatigue Syndrome; Multiple Sclerosis; Healthy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18 to 65 years of age
  • Healthy volunteer OR Clinical diagnosis of Multiple Sclerosis (MS) OR Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome

Exclusion Criteria

  • Contraindication to MRI
  • Pregnancy
  • Lactation
  • Individuals who are unable to participate in the imaging portion due to severity of their medical condition
  • Chronic infectious disease (e.g. HIV, HCV)
  • Viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation
  • Diagnosis of cancer, including leukemia
  • Blood or blood clotting disorder
  • Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary
  • Positive urine β-hCG test day of procedure or a serum -hCG test within 48 hours prior to the administration of [18F]DPA-714
  • Currently enrolled in a clinical trial utilizing experimental therapies

Recruiting US locations

  • University of Alabama at Birmingham Medical Center

    Birmingham, AL 35294

    Site contact: Jonathan McConathy, MD · 205-996-7115 · jmcconathy@uabmc.edu

Study contacts (from the official record)

  • Jared Younger, PhD · 205-975-5907 · youngerlab@uab.edu
All neurology studies in Alabama →
Assessment of Neuroinflammation in Central Inflammatory Disorders… (NCT03759522) | Bored Studies